Your browser is no longer supported. Please, upgrade your browser.
Atea Pharmaceuticals, Inc.
Index- P/E99.44 EPS (ttm)0.40 Insider Own18.48% Shs Outstand82.74M Perf Week-1.95%
Market Cap3.33B Forward P/E2.52 EPS next Y15.60 Insider Trans0.00% Shs Float67.48M Perf Month44.78%
Income35.30M PEG- EPS next Q-0.17 Inst Own69.10% Short Float9.59% Perf Quarter57.75%
Sales175.00M P/S19.03 EPS this Y23.60% Inst Trans-2.85% Short Ratio3.61 Perf Half Y-11.73%
Book/sh7.23 P/B5.43 EPS next Y2589.66% ROA5.30% Target Price51.00 Perf Year-
Cash/sh9.63 P/C4.08 EPS next 5Y- ROE8.50% 52W Range18.72 - 94.17 Perf YTD-5.98%
Dividend- P/FCF- EPS past 5Y- ROI-2.00% 52W High-58.29% Beta-
Dividend %- Quick Ratio3.20 Sales past 5Y- Gross Margin- 52W Low109.83% ATR3.16
Employees49 Current Ratio3.20 Sales Q/Q- Oper. Margin- RSI (14)58.08 Volatility6.39% 9.47%
OptionableYes Debt/Eq0.00 EPS Q/Q114.10% Profit Margin20.20% Rel Volume0.64 Prev Close40.45
ShortableYes LT Debt/Eq0.00 EarningsAug 12 AMC Payout0.00% Avg Volume1.79M Price39.28
Recom1.60 SMA208.86% SMA5022.48% SMA200-5.14% Volume1,154,321 Change-2.89%
Oct-05-21Downgrade Morgan Stanley Overweight → Equal-Weight $55
Nov-25-20Initiated Evercore ISI Outperform
Nov-24-20Initiated William Blair Outperform $60
Nov-24-20Initiated Morgan Stanley Overweight $49
Nov-24-20Initiated JP Morgan Overweight $45
Oct-15-21 04:30PM  
Oct-12-21 04:00PM  
Oct-11-21 08:27AM  
Oct-08-21 08:30AM  
Oct-07-21 07:00AM  
Oct-05-21 10:00AM  
Oct-04-21 10:00AM  
Oct-03-21 04:00PM  
Oct-01-21 12:21PM  
Sep-29-21 07:00AM  
Sep-20-21 01:18PM  
Sep-18-21 12:11PM  
Sep-10-21 12:19PM  
Sep-07-21 07:00AM  
Aug-24-21 07:00AM  
Aug-13-21 01:37AM  
Aug-12-21 04:05PM  
Aug-05-21 07:00AM  
Aug-04-21 09:39AM  
Jul-12-21 07:00AM  
Jun-30-21 11:11AM  
Jun-16-21 09:26AM  
Jun-15-21 07:00AM  
May-26-21 07:00AM  
May-25-21 12:41AM  
May-20-21 07:00AM  
May-15-21 03:26AM  
May-13-21 04:05PM  
May-06-21 07:00AM  
Apr-29-21 06:44AM  
Apr-22-21 06:25AM  
Apr-21-21 05:15AM  
Apr-16-21 06:49AM  
Apr-14-21 09:40AM  
Apr-08-21 01:24AM  
Mar-31-21 02:00AM  
Mar-30-21 04:01PM  
Mar-23-21 07:00AM  
Mar-06-21 07:00AM  
Feb-19-21 08:30AM  
Feb-09-21 08:09AM  
Feb-08-21 04:01PM  
Feb-04-21 07:00AM  
Jan-30-21 01:30AM  
Jan-26-21 06:20AM  
Jan-19-21 07:00AM  
Dec-21-20 08:48AM  
Dec-18-20 08:00AM  
Nov-25-20 07:00AM  
Nov-20-20 07:54PM  
Nov-06-20 08:00AM  
Nov-03-20 04:01PM  
Nov-01-20 09:29PM  
Oct-29-20 08:00PM  
Atea Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focused on discovering, developing, and commercializing antiviral therapeutics for patients suffering from viral infections. Its lead product candidate is AT-527, a novel antiviral agent that is in Phase II clinical trial for the treatment of patients with COVID-19. The company also develops AT-752, an oral purine nucleoside prodrug product candidate, which has completed Phase Ia clinical trial for the treatment of dengue; AT-787, a co-formulated, oral, pan-genotypic fixed dose combination of AT-527 and AT-777 that is in Phase I/IIa clinical trial for the treatment of chronic hepatitis C; and AT-889, an investigational, second-generation nucleoside pyrimidine prodrug and other compounds for the treatment of respiratory syncytial virus. It has a Roche License Agreement with F. Hoffmann-La Roche Ltd and Genentech, Inc. for development and commercialization related to AT-527 outside of the United States. The company was incorporated in 2012 and is headquartered in Boston, Massachusetts.